Literature DB >> 15744072

Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus.

Sadahiko Shimoeda1, Shin Ohta, Hikaru Kobayashi, Hiroshi Saitou, Ai Kubota, Susumu Yamato, Kenji Shimada, Mutsuko Sasaki, Kenji Kawano.   

Abstract

In 29 patients (40 samples) with hematological diseases who had been treated with a candin antifungal agent, micafungin (MCFG), we measured the blood level of MCFG by high-performance liquid chromatography (HPLC). There was a correlation between the dose and the blood level of MCFG (r = 0.729, p < 0.001). In addition, there was a correlation between the total bilirubin level and the C/D value (r = 0.458, p < 0.01), which was calculated by dividing the blood level of MCFG by the dose, although there was no correlation between creatinine clearance and the C/D value. These findings suggest that the dose of MCFG must be regulated in patients with biliary stasis-type liver hypofunction. In addition, there was no significant difference in the blood level of MCFG between the group in which tacrolimus (FK506) was combined with MCFG and the group in which MCFG alone was administered. These results suggest that there are no changes in the blood level of MCFG even when MCFG is combined with FK506.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744072     DOI: 10.1248/bpb.28.477

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

Review 1.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

2.  Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.

Authors:  Kimitaka Suetsugu; Hiroaki Ikesue; Toshihiro Miyamoto; Motoaki Shiratsuchi; Nanae Yamamoto-Taguchi; Yuichi Tsuchiya; Kumi Matsukawa; Mayako Uchida; Hiroyuki Watanabe; Koichi Akashi; Satohiro Masuda
Journal:  Int J Hematol       Date:  2016-11-07       Impact factor: 2.490

Review 3.  Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.

Authors:  Sarah A Cross; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies.

Authors:  Yasunori Nakagawa; Yoko Ichii; Yasuhiro Saeki; Masanobu Kodama; Satoshi Kishino; Kenshi Suzuki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.

Authors:  Roeland E Wasmann; Eline W Muilwijk; David M Burger; Paul E Verweij; Catherijne A Knibbe; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.